{"id":7298,"date":"2023-01-25T15:59:00","date_gmt":"2023-01-25T22:59:00","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/pacificnwandseattleguild\/?p=7298"},"modified":"2025-12-01T20:27:20","modified_gmt":"2025-12-01T20:27:20","slug":"portland-spokane-seattle-dream-study-for-diabetic-retinopathy","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2023\/01\/25\/portland-spokane-seattle-dream-study-for-diabetic-retinopathy\/","title":{"rendered":"Portland, Spokane & Seattle – DR:EAM Study for Diabetic Retinopathy"},"content":{"rendered":"

For people living with type 1 diabetes (T1D), external doses of insulin save their lives\u2014every day. Yet keeping blood-sugar levels within a healthy range remains a daily challenge, putting them at risk of both short- and long-term complications. Breakthrough T1D is committed to making the management of T1D much better and safer through research and clinical trials to develop new therapies that can help keep your blood-sugar levels in range, reduce insulin dosage, and decrease complications that come from the disease.<\/p>\n

One very common long-term complication of T1D is diabetic retinopathy<\/strong>.\u00a0 Diabetic retinopathy (DR) occurs when the blood vessels at the back of the eye (the retina) are damaged. If left undiagnosed and untreated, DR can lead to visual problems and even blindness. The retina is the part of the eye that senses light. It sends electrical signals to the brain to interpret what is seen and creates an image.\u00a0 People with DR may have a loss of central vision, blurred vision, or other visual disturbances (floaters or black spots).<\/p>\n

The majority of people with DR are of working age (18 to 65 years). As such, approved treatments that have minimal side effects and do not have a big impact on daily activities are highly desirable.\u00a0 The current standard of care involves injections into the eye once patients develop severe disease and\/or experience vision loss.\u00a0 The DR:EAM Study<\/strong> is looking at a less invasive approach with an eye drop that can be used at an earlier stage of DR.\u00a0 This is a multi-site study, including participating sites in Portland, Spokane and Seattle.<\/p>\n

 <\/p>\n

THE STUDY:<\/strong><\/p>\n

Aim<\/u><\/strong><\/p>\n

In the DR:EAM Study, the use of an investigational topical eye drop will be assessed in men and women with type 1 or 2 diabetes mellitus who also have DR and who have not received any previous treatment for their DR.<\/p>\n

Participants <\/u><\/strong><\/p>\n

Around 210 men and women in the United States are expected to take part in the DR:EAM Study.<\/p>\n

Inclusion Criteria<\/u><\/strong><\/p>\n

To take part in the DR:EAM Study, you must:<\/p>\n